[{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Vipragen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangoceuticals \/ Vipragen Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Mangoceuticals \/ Vipragen Biosciences"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Boustead Securities","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Greater NY Chamber of Commerce","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Greater NY Chamber of Commerce","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Greater NY Chamber of Commerce"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"||PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clomiphene Citrate","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangoceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mangoceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Mangoceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : Company is evaluating a patented respiratory illness prevention technology against the H5N1 virus (Avian Influenza) infection.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 06, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Vipragen Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : Prime (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

                          Product Name : Prime

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          December 03, 2024

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : Mojo (enclomiphene citrate, pregnenolone and dehydroepiandrosterone) is an oral dissolvable tablet aimed at restoring hormonal balance and naturally increasing testosterone levels in men.

                          Product Name : Mojo

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 06, 2024

                          Lead Product(s) : Clomiphene Citrate,Dehydroepiandrosterone,Pregnenolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : The Company intends to use the net proceeds to finance the marketing and operational expenses associated with the planned marketing of its Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dy...

                          Product Name : Tadalafil Mango

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 15, 2023

                          Lead Product(s) : Tadalafil,L-Arginine,Oxytocin

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Boustead Securities

                          Deal Size : $1.2 million

                          Deal Type : Public Offering

                          blank

                          05

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : The partnership aims bring its flagship product, Mango, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction, to New York.

                          Product Name : Tadalafil Mango

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 08, 2023

                          Lead Product(s) : Tadalafil,L-Arginine,Oxytocin

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Greater NY Chamber of Commerce

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : Mango (sildenafil citrate) mango-flavored, rapid dissolve tablet is a Phosphodiesterase-5 inhibitor, which is being indicated for the treatment of erectile dysfunction.

                          Product Name : Mango

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 16, 2023

                          Lead Product(s) : Sildenafil Citrate,L-Arginine,Oxytocin

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank